Literature DB >> 17691766

MO tripeptide diastereomers (M=99/99mTc, Re): models to identify the structure of 99mTc peptide targeted radiopharmaceuticals.

Melchor V Cantorias1, Robertha C Howell, Louis Todaro, John E Cyr, Dietmar Berndorff, Robin D Rogers, Lynn C Francesconi.   

Abstract

Biologically active molecules, such as many peptides, serve as targeting vectors for radiopharmaceuticals based on 99mTc. Tripeptides can be suitable chelates and are easily and conveniently synthesized and linked to peptide targeting vectors through solid-phase peptide synthesis and form stable TcVO complexes. Upon complexation with [TcO]3+, two products form; these are syn and anti diastereomers, and they often have different biological behavior. This is the case with the approved radiopharmaceutical [99mTcO]depreotide ([99mTcO]P829, NeoTect) that is used to image lung cancer. [99mTcO]depreotide indeed exhibits two product peaks in its HPLC profile, but assignment of the product peaks to the diastereomers has proven to be difficult because the metal peptide complex is difficult to crystallize for structural analysis. In this study, we isolated diastereomers of [99TcO] and [ReO] complexes of several tripeptide ligands that model the metal chelator region of [99mTcO]depreotide. Using X-ray crystallography, we observed that the early eluting peak (A) corresponds to the anti diastereomer, where the Tc=O group is on the opposite side of the plane formed by the ligand backbone relative to the pendant groups of the tripeptide ligand, and the later eluting peak (B) corresponds to the syn diastereomer, where the Tc=O group is on the same side of the plane as the residues of the tripeptide. 1H NMR and circular dichroism (CD) spectroscopy report on the metal environment and prove to be diagnostic for syn or anti diastereomers, and we identified characteristic features from these techniques that can be used to assign the diastereomer profile in 99mTc peptide radiopharmaceuticals like [99mTcO]depreotide and in 188Re peptide radiotherapeutic agents. Crystallography, potentiometric titration, and NMR results presented insights into the chemistry occurring under physiological conditions. The tripeptide complexes where lysine is the second amino acid crystallized in a deprotonated metallo-amide form, possessing a short N1-M bond. The pKa measurements of the N1 amine (pKa approximately 5.6) suggested that this amine is rendered more acidic by both metal complexation and the presence of the lysine residue. Furthermore, peptide chelators incorporating a lysine (like the chelator of [TcO]depreotide) likely exist in the deprotonated form in vivo, comprising a neutral metal center. Deprotonation possibly mediates the interconversion process between the syn and anti diastereomers. The N1 amine group on non-lysine-containing metallopeptides is not as acidic (pKa approximately 6.8) and does not deprotonate and crystallize as do the metallo-amide species. Three of the tripeptide ligands (FGC, FSC, and FKC) were radiolabeled with 99mTc, and the individual syn and anti isomers were isolated for biodistribution studies in normal female nude mice. The main organs of uptake were the liver, intestines, and kidneys, with the FGC compounds exhibiting the highest liver uptake. In comparing the diastereomers, the syn compounds had substantially higher organ uptake and slower blood clearance than the anti compounds.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17691766      PMCID: PMC2270398          DOI: 10.1021/ic070077p

Source DB:  PubMed          Journal:  Inorg Chem        ISSN: 0020-1669            Impact factor:   5.165


  28 in total

1.  Targeting hypoxia in tumors using 2-nitroimidazoles with peptidic chelators for technetium-99m: effect of lipophilicity.

Authors:  X Zhang; Z F Su; J R Ballinger; A M Rauth; A Pollak; J R Thornback
Journal:  Bioconjug Chem       Date:  2000 May-Jun       Impact factor: 4.774

2.  Availability of rhenium-188 from the alumina-based tungsten-188/rhenium-188 generator for preparation of rhenium-188-labeled radiopharmaceuticals for cancer treatment.

Authors:  F F Knapp; A L Beets; S Guhlke; P O Zamora; H Bender; H Palmedo; H J Biersack
Journal:  Anticancer Res       Date:  1997 May-Jun       Impact factor: 2.480

3.  New brain perfusion imaging agents based on 99mTc-bis(aminoethanethiol) complexes: stereoisomers and biodistribution.

Authors:  H F Kung; Y Z Guo; C C Yu; J Billings; V Subramanyam; J C Calabrese
Journal:  J Med Chem       Date:  1989-02       Impact factor: 7.446

4.  In vivo evaluation of 99mTc/188Re-labeled linear alpha-melanocyte stimulating hormone analogs for specific melanoma targeting.

Authors:  J Chen; M F Giblin; N Wang; S S Jurisson; T P Quinn
Journal:  Nucl Med Biol       Date:  1999-08       Impact factor: 2.408

5.  Technetium-99m N,N'-bis(2-mercapto-2-methylpropyl)-2-aminobenzylamine: technetium-99m complexes of a novel bis(aminoethanethiol) ligand.

Authors:  L C Francesconi; Y Y Yang; M P Kung; X X Zhang; J J Billings; Y Z Guo; H F Kung
Journal:  J Med Chem       Date:  1994-09-30       Impact factor: 7.446

6.  Rhenium(V) and Technetium(V) Oxo Complexes of an N(2)N'S Peptidic Chelator: Evidence of Interconversion between the Syn and Anti Conformations.

Authors:  Ernest Wong; Theresa Fauconnier; Samantha Bennett; John Valliant; Tam Nguyen; Frank Lau; Linda F. L. Lu; Alfred Pollak; Russell A. Bell; John R. Thornback
Journal:  Inorg Chem       Date:  1997-12-03       Impact factor: 5.165

7.  Somatostatin receptor-binding peptides suitable for tumor radiotherapy with Re-188 or Re-186. Chemistry and initial biological studies.

Authors:  John E Cyr; Daniel A Pearson; David M Wilson; Carol A Nelson; Mary Guaraldi; Michael T Azure; John Lister-James; Ludger M Dinkelborg; Richard T Dean
Journal:  J Med Chem       Date:  2007-02-22       Impact factor: 7.446

8.  Preparation and characterization of [99TcO] apcitide: a technetium labeled peptide.

Authors:  Lynn C Francesconi; Yongyong Zheng; Judit Bartis; Michael Blumenstein; Catherine Costello; Mark A De Rosch
Journal:  Inorg Chem       Date:  2004-05-03       Impact factor: 5.165

9.  Dicarboxylate diamide dimercaptide (N2S2) technetium-99m complexes: synthesis and biological evaluation as potential renal radiopharmaceuticals.

Authors:  D J Canney; J Billings; L C Francesconi; Y Z Guo; B S Haggerty; A L Rheingold; H F Kung
Journal:  J Med Chem       Date:  1993-04-16       Impact factor: 7.446

10.  Technetium-99m HM-PAO stereoisomers as potential agents for imaging regional cerebral blood flow: human volunteer studies.

Authors:  P F Sharp; F W Smith; H G Gemmell; D Lyall; N T Evans; D Gvozdanovic; J Davidson; D A Tyrrell; R D Pickett; R D Neirinckx
Journal:  J Nucl Med       Date:  1986-02       Impact factor: 10.057

View more
  5 in total

1.  Synthesis and evaluation of novel Tc-99m labeled probestin conjugates for imaging APN/CD13 expression in vivo.

Authors:  Gopal Pathuri; Andria F Hedrick; Bryan C Disch; John T Doan; Michael A Ihnat; Vibhudutta Awasthi; Hariprasad Gali
Journal:  Bioconjug Chem       Date:  2011-12-20       Impact factor: 4.774

2.  Synthesis, characterization and biological studies of rhenium, technetium-99m and rhenium-188 pentapeptides.

Authors:  Vanessa A Sanders; David Iskhakov; Dalya Abdel-Atti; Matthew Devany; Michelle C Neary; Ken R Czerwinski; Lynn C Francesconi
Journal:  Nucl Med Biol       Date:  2018-11-12       Impact factor: 2.408

3.  Binding of ReO4(-) with an engineered MoO4(2-)-binding protein: towards a new approach in radiopharmaceutical applications.

Authors:  Baikuntha P Aryal; Pedro Brugarolas; Chuan He
Journal:  J Biol Inorg Chem       Date:  2011-08-23       Impact factor: 3.358

4.  Inorganic chemistry in nuclear imaging and radiotherapy: current and future directions.

Authors:  Valerie Carroll; Dustin W Demoin; Timothy J Hoffman; Silvia S Jurisson
Journal:  Radiochim Acta       Date:  2012-08       Impact factor: 1.440

5.  Isolation, characterization, and biological evaluation of syn and anti diastereomers of [(99m)Tc]technetium depreotide: a somatostatin receptor binding tumor imaging agent.

Authors:  John E Cyr; Daniel A Pearson; Carol A Nelson; Barbara A Lyons; Yongyong Zheng; Judit Bartis; Jiafang He; Melchor V Cantorias; Robertha C Howell; Lynn C Francesconi
Journal:  J Med Chem       Date:  2007-08-11       Impact factor: 7.446

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.